In Thrombolysis in Myocardial Infarction (TIMI) Phase I, 290 patients with acute myocardial infarction were randomized to either intravenous recombinant tissue-type plasminogen activator @t-PA) or intravenous streptokinase. Two hundred twenty-nine patients had radionuclide ventriculograms at discharge for assessment of global and regional left ventricular ejection fraction. Among these 229 patients 185 had totally occluded infarct-related arteries, and angiographic reperfusion of the infarct-related artery occurred in 69% of patients treated with rt-PA and 28% of patients treated with streptokinase (p < 0.001).
In Thrombolysis in Myocardial Infarction (TIMI) Phase I, 290 patients with acute myocardial infarction were randomized to either intravenous recombinant tissue-type plasminogen activator @t-PA) or intravenous streptokinase. Two hundred twenty-nine patients had radionuclide ventriculograms at discharge for assessment of global and regional left ventricular ejection fraction. Among these 229 patients 185 had totally occluded infarct-related arteries, and angiographic reperfusion of the infarct-related artery occurred in 69% of patients treated with rt-PA and 28% of patients treated with streptokinase (p < 0.001).
Mean global left ventricular ejection fraction was not different for rt-PA-treated patients compared with strep tokinase-treated patients (0.46 versus 0.45). However, the average regional ejection fraction of the regions subtended by the infarct-related artery showed a trend toward better average infarct region ejection fraction in patients treated with rt-PA than in patients treated with streptokinase (0.40 versus 0.36; 0.05 < p < 0.06). Analysis of data according to perfusion status of the infarct-related artery showed no difference in mean global left ventricular ejection fraction between patients with sustained versus nonsustained reperfusion (0.47 versus 0.44). However, there was better average regional ejection fraction of the region subtended by the infarct-related artery in patients with sustained reperfusion (0.40 versus 0.36; p < 0.01).
Thus, quantitation of regional left ventricular function by radionuclide techniques provides a noninvasive means for evaluating the effects of thrombolysis. This study suggests a direct relation between improvement of regional left ventricular function and the greater infarct-related artery patency rate achieved by rt-PA compared with streptokinase.
(. I Am Co11 Cardiol1989; 13:998-1005) The Thrombolysis in Myocardial Infarction (TIMI) trial has been in progress since August 1984 . Phase I, completed in February 1985 , was conducted to establish the relative thrombolytic attributes of intravenous recombinant tissue-type plasminogen activator (rt-PA) in comparison with intravenous streptokinase with use of coronary angiographic evidence of infarct-related vessel patency as the primary study end point. In the TIM1 Phase I trial, it was demonstrated that significantly greater recanalization rates occurred after treatment with rt-PA than with streptokinase (l-3). This difference was observed earlier than expected, and the study was terminated before the anticipated total patient enrollment was achieved. During the course of the study, contrast and radionuclide angiocardiography were performed to provide secondary end point information concerning the effect of therapy on left ventricular function. According to protocol, cardiac catheterization and contrast ventriculography were performed before therapy and again at hospital discharge, whereas radionuclide angiocardiogra-phy was performed only at the time of hospital discharge. The results of contrast left ventricular angiography in Phase 1 have been reported (4). The present report describes the results of radionuclide assessment of left ventricular function in TIMI Phase I patients at hospital discharge. Global function was defined by left ventricular ejection fraction, whereas regional function was measured by regional count-based ejection fraction. These functional variables are compared in patients receiving rt-PA and in those receiving streptokinase, as well as in patients with and without successful reperfusion.
Methods
Study patients. The TIMI protocol has been described in detail previously (3). Patients were included in the Phase 1 TIM1 trial if they had chest pain lasting ~30 min, and ST segment elevation ~0.1 mV in at least two leads on the admission electrocardiogram (ECG). If more than 7 h had elapsed since the onset of chest pain, patients were not eligible. Other exclusion criteria were age >75 years, uncontrolled hypertension, cerebrovascular events, severe streptococcal infection, other advanced illness, previous streptokinase infusion, severe trauma within the last 6 months, current oral anticoagulant therapy, past or present bleeding disorder or significant gastrointestinal bleeding, surgery or cardiopulmonary resuscitation within the 2 weeks preceding admission, prior coronary artery bypass surgery, left bundle branch block, prosthetic heart valve, dilated cardiomyopathy and shock unresponsive to volume expansion or vasopressor therapy.
After providing informed consent, eligible patients were immediately transferred to the cardiac catheterization laboratory. A 5,000 U intravenous bolus of heparin was given. Left ventriculography was performed in the 30" right anterior oblique projection. Angiograms of the noninfarct-and infarct-related coronary arteries (as judged from ECG and regional wall motion abnormality on the ventriculogram) were obtained in multiple views. Patients with ~50% diameter reduction of the infarct-related artery at baseline study or after intracoronary nitroglycerin (200 pg) were not given thrombolytic agents. The remaining patients were assigned to either streptokinase (Hoechst-Roussel Pharmaceuticals or Kabi Vitrum) or rt-PA (Genentech, Inc.). Streptokinase was administered as 1.5 million U intravenously over 1 h. Roller bottle method-produced rt-PA (GII021) was given intravenously over a 3 h period: 40,20 and 20 mg in the I st, 2nd and 3rd h, respectively. To maintain blinding, each patient received both an active agent and a placebo in concomitant 1 and 3 h infusions through separate intravenous lines. A coronary angiogram of the infarct-related artery was obtained 10, 20. 30. 45. 60, 75 and 90 min after initiation of thrombolytic therapy. Coronary angiography and ventriculography were repeated at the time of hospital (usually 8 to IO days after infarction).
discharge
After coronary angiography during the acute phase of infarction, the patients received routine coronary care plus intravenous heparin at 1,000 U/h beginning 3 h after the initial bolus with the dose adjusted as needed to maintain partial thromboplastin time at 1.5 to 2 times normal for 5 days. ,411 other therapies were administered according to guidelines written in the TIM1 Manual of Operations: these guidelines specifically addressed antiarrhythmic agents (for example, lidocaine) and antianginal agents (for example, nitrates, beta-adrenergic blockers and calcium channel blockers). No important differences existed in concomitant therapies between the double-blind randomized treatment groups.
Radionuclide angiocardiography. Equilibrium radionuelide angiocardiography was performed before hospital discharge (mean 9.6 days after study entry). In all I3 participating centers. the procedure was performed according to a standardized protocol. The patients' own red blood cells were labeled with technetium-99m with use of a modified in vivo technique: 15 min after injection of stannous pyrophosphate (SO mg intravenously). IO cc of blood was withdrawn into a syringe containing 30 mCi of technetium-99m pertechnetate and 1 ml of anticoagulant citrate dextrose solution. The blood was incubated in the syringe for IO min, and then reinjected into the patient with saline flush (5). Radionuclide angiocardiography was performed with a scintillation camera equipped with a general, all purpose. parallel hole collimator interfaced with a dedicated minicomputer. The energy window (20%) was set over 140 keV. Image acquisition was done in four projections: left anterior oblique projection (angulation that best separated the right and left ventricles), anterior projection (45" to the right of the angulation for the left anterior oblique projection), left lateral projection (with the patient lying on the right side and the gamma detector in the same angulation as for the anterior view) (6) and left posterior oblique projection (30" posterior of the left lateral projection). All data were acquired in ECG-synchronized frame mode in 64 x 64 matrix (word mode). At least 16 frames/RR interval were acquired. Each frame was ~40 ms. The unsmoothed studies were stored on magnetic tape or floppy disk and mailed to the radionuclide core laboratory at Yale University for analysis.
Quantitative analysis. The studies analyzed in the radionuclide core laboratory were identified only by code name and number; no clinical information was provided. In the radionuclide core laboratory, studies were transcribed to a central computer for temporal and spatial filtering and displayed as an endless loop movie.
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1)
Global left ventricular ejection fraction was determined from the left anterior oblique projection. with use of previously validated automated computer software (General Electric, PAGE) (7). In brief, after filtering of the images, the center of the left ventricle is automatically found by the computer. From this center, the left ventricular perimeter (second derivative points) is identified along radii in each frame of the cardiac cycle. Correction for background activity is performed by interpolative subtraction. Finally, a left ventricular volume curve is generated over the regions of interest of the left ventricle. From this curve, global left ventricular ejection fraction is calculated in the standard fashion: (end-diastolic counts minus end-systolic counts)/end-diastolic counts. 2) Regional left ventricular ejection fraction was obtained from the left anterior oblique projection by dividing the end-diastolic region of interest in five segments: basal septal, apical septal, inferoapical, inferolateral and posterolateral. The area involving the valve plane was excluded ( Fig. 1 ). Regional ejection fraction was calculated from maximal and minimal counts in all regions.
For each patient, the average regional ejection fraction of the myocardial infarct zone also was determined. This value was based on the relation between the location of the sector of the left anterior oblique left ventricular blood pool used for the regional ejection fraction and the anatomic location of the infarct. For right coronary artery-related infarcts, the average of the inferoapical and inferolateral segments was chosen. For left anterior descending arteryrelated infarcts, an average of the basal septal and apical septal regions was chosen, and for left circumflex arteryrelated infarcts, the posterolateral segment was chosen. For the entire group, with use of this technique, an average of the myocardial infarct zone regional ejection fractions could then analyze regional function as it related to the infarct zone alone.
Angiographic and clinical definitions. The degree of coronary reperfusion after thrombolytic therapy and the extent of collateral vesselformation on the angiograms were graded (grade 0, 1, 2 or 3) according to standardized criteria in the TIMI trial (l-4).
Reperfusion status. Sustained reperfusion was defined as follows: coronary perfusion was grade 2 or 3 at 90 min after initiation of treatment and at hospital discharge, and there were no reocclusion events (angiographic occlusion or clinical reinfarction) for 21 days after the onset of chest pain. Alternatively, coronary perfusion was grade 2 or 3 at 90 min after initiation of thrombolytic therapy, there were no angiographic data at discharge and no reinfarction occurred clinically for 21 days after the onset of chest pain. Data analysis. Global and regional left ventricular function were compared with respect to type of thrombolytic agent used. Because the response of these variables depends on the success or failure of thrombolytic therapy, they were also analyzed in relation to reperfusion status of the infarctrelated artery. Moreover, because the impact of successful reperfusion on global and regional left ventricular function may depend on which artery is infarct-related, these variables were also analyzed in relation to reperfusion status of the specijk infarct-related artery (left anterior descending, left circumflex or right coronary artery).
Because TIMI Phase I was designed to detect differences in reperfusion regardless of infarct-related artery and was stopped early because of large differences in reperfusion rates favoring rt-PA, there are too few observations for each region of the myocardium and for each infarct-related artery to analyze regional wall motion in each area with appropriate statistical power. On the basis of experience with reliability of global ejection fraction measurements obtained with radionuclide ventriculography in patients with a normal or abnormal ejection fraction (7), a "trend" in global or regional wall motion has been arbitrarily defined as a difference of r3 units if associated with a probability (p) value ~0.10. These p values are provided as descriptive statistics with no adjustment for multiple comparisons.
To summarize the effects of treatment on regional ejection fraction for the ventricular wall segments associated with the infarct-related artery, a regression analysis (8) was
performed with t/w following model: regional ejection fraction = a constant intercept t treatment effect t infarctrelated artery effect + random error. The treatment effect analyzed with this model compared streptokinase and rt-PA. Also compared with this model were sustained reperfusion with nonsustained reperfusion and collateral circulation present with no collateral circulation present. The infarctrelated artery is included in this model as a covariate because of large differences in regional ejection fraction associated with the three infarct-related coronary arteries.
To 
Results
Patient characteristics (Table 1) . Two hundred ninety patients with acute myocardial infarction were treated according to random assignment in TIM1 Phase I with either intravenous rt-PA (n = 143) or intravenous streptokinase (n = 147). Two hundred twenty-nine patients (79%) had a radionuclide ventriculogram at hospital discharge. The 61 patients without a discharge radionuclide ventriculogram included 12 patients who died during the first 21 days after infarction, 12 who had coronary bypass surgery in this period and 37 who either did not undergo radionuclide study or had an inadequate study because of technical difficulties. The clinical characteristics of the 290 patients with or without a discharge radionuclide study are summarized in Table 1 . Patients with this study had a greater frequency of clinically sustained reperfusion and fewer cardiac events than did those who were not studied.
Results of thrombolytic therapy (Table 2) . Among the 229 patients with a discharge radionuclide ventriculogram, 185 had totally occluded infarct-related arteries (grade 0 or I) at presentation. Of these 185 patients, 90 treated with rt-PA had significantly more frequent angiographic reperfusion of the infarct-related artery than did the 95 patients treated with streptokinase (69% versus 287~~ p < 0.001). These reperfusion rates are similar to those observed in the entire study group of 290 patients (I ,3). The time from onset of chest pain to treatment was not different for the two groups (4.8 versus 4.9 h. p = NS). The clinical and angiographic variables of both treatment groups and the time to onset of treatment are shown in Table 2 . Among patients for whom radionuclide left ventricular ejection fraction was obtained. treatment with rt-PA resulted in a significantly higher frequency of reperfusion of the infarct-related artery than that obtained with streptokinase in patients treated <4 h and r4 h after the onset of chest pain.
Effect of thrombolytic therapy on global and regional left ventricular function at hospital discharge (Tables 3 and 4).
Despite differences in reperfusion rates noted in the two treatment groups, mean global left ventricular ejection frac- *Applies to all percents except reperfusion at 90 min: tpercent of patients with one, two or three vessels with stenosis >70%; $grade 2 or 3 perfusion at 90 min. no reocclusion events for 21 days after the onset of chest pain and no occlusion found at hospital discharge. If not indicated p = NS. r&PA = recombinant tissue-type plasminogen activator; SK = streptokinase; other abbreviations as in Table I. tion at discharge was not different for patients treated with rt-PA or streptokinase (0.46 versus 0.45, p = NS) (Table 3) . Imputed global ejection fraction included data from 274 patients (94%) in the analysis, and was not different in the two groups (0.44 versus 0.42, p = NS). However, mean regional left ventricular ejection fraction in the apical septal area tended to be better in patients treated with rt-PA than in those treated with streptokinase (0.39 versus 0.35, p = 0.06). Similarly, there was a trend toward better inferoapical mean regional left ventricular ejection fraction in patients treated with r&PA than in those treated with streptokinase (0.43 versus 0.38, p = 0.08). (Table 4 ). There were no appreciable differences in global ejection fraction in any arterial distribution. There was a regional ejection fraction trend in the apical septal region (0.45 versus 0.39, p = 0.09) favoring treatment with rt-PA over treatment with strepto- When the average regional ejection fraction of the regions subtended by the infarct-related artery (inferoapical and inferolateral for right coronary artery, basal septal and apical septal for left anterior descending coronary artery and posterolateral for left circumflex coronary artery) was considered, there was a trend toward better average infarct region ejection fraction in patients treated with t-t-PA than in patients treated with streptokinase (0.40 versus 0.36, p = 0.08). Regression analysis to adjust for the infarct-related artery did not change this trend (0.05 < p < 0.06).
The impact of treatment was further evaluated according to the speci'c infarct-related artery
Analysis of subgroups: perfusion status. The ultimate outcome of patients receiving thrombolytic therapy depends on whether successful reperfusion was achieved. Therefore, further subgroup analysis was performed based on perfusion status, irrespective of the type of thrombolytic agent.
There was little difference in mean global left ventricular ejection fraction at hospital discharge in 107 patients who had sustained reperfusion (Table 3) (Table 5 ). There was no difference in mean global left ventricular ejection fraction in patients with and those without collateral vessels to the infarct zone (0.47 versus 0.45, p = NS). Regional left ventricular ejection fraction in the posterolateral segment was better in patients with collateral vessels (0.58 versus 0.54, p = 0.05) than in patients without collateral circulation to the infarct zone. However, there were no appreciable differences in the remaining segments: basal septal, apical septal. inferoapical and inferolateral in patients with and without collateral vessels to the infarct region. When average myocardial infarct regional ejection fraction for the regions subtended by the infarct artery was considered, there was no difference between patients with collateral circulation as opposed to those without (0.39 versus 0.38, p = NS), and no statistical significance emerged with adjustment for the infarct-related artery.
Discussion
Thrombolysis and regional left ventricular function. The ultimate goal of thrombolytic therapy in acute myocardial infarction is to salvage jeopardized ischemic myocardium and, by so doing, improve short-and long-term prognosis. Because left ventricular performance is a determinant of postinfarction prognosis, assessment of global and regional left ventricular function is appropriate for evaluating the effects of thrombolytic therapy. The evaluation of regional left ventricular function is important because segmental improvement of left ventricular function is not always reflected by improvement of global left ventricular ejection fraction (18). Compensating hyperkinesia in the noninfarct zone may subside, while function in the infarct zone itself improves. In the present study, in addition to global left ventricular ejection fraction, we employed a count-based regional left ventricular ejection fraction to evaluate regional left ventricular function.
Radionuclide ventriculograpby. In Phase I of the TIMI trial, both contrast ventriculography and radionuclide ventriculography were performed. Although contrast ventriculography has the advantage of higher resolution images compared with radionuclide studies, radionuclide studies have the advantage of being less invasive and hence easier to perform in large numbers of patients. Another advantage, although not employed in TIM1 Phase I, is that radionuclide ventriculography can be combined with exercise evaluation to obtain further information about the existence of residual ischemic myocardium and prognosis (1 l-13).
rt-PA compared with streptokinase. In the present study, global and regional left ventricular function were compared in patients treated with streptokinase or rt-PA. In addition, comparisons were made in several nonrandomized subgroups (that is, between patients with sustained or nonsustained reperfusion, among patients with different infarctrelated arteries and between patients with or without collateral circulation). Although significantly more successful reperfusion was observed in patients treated with rt-PA compared with those treated with streptokinase, mean differences in global left ventricular ejection fraction between the two patient groups were not statistically significant. However, trends in regional left ventricular ejection fraction favored patients who received rt-PA, and average regional ejection fraction in the specific infarct regions favored patients treated with rt-PA over patients treated with streptokinase .
Reperfusion status. When patients were analyzed according to reperfusion status, patients who had successful sustained reperfusion of the infarct-related artery had significantly better regional left ventricular function than did patients who did not have reperfusion. When patients were analyzed according to the specific infarct-related coronary artery, trends toward better global left ventricular ejection fraction were observed in patients with a right coronary artery or left anterior descending coronary infarct who had sustained reperfusion. The possible benefit to patients with sustained reperfusion must be interpreted with caution because these patients were selected by a definition that included survival for 3 weeks after study entry. These patients could be expected by their selection to have better cardiac function in addition to any effects of reperfusion.
Study design. All observed differences in global and regional function were rather modest. It is likely that this finding is related to the TIM1 Phase I protocol, which was designed to evaluate the relative efficacy of intravenous streptokinase and intravenous t-t-PA in achieving thrombolysis and reperfusion of infarct-related arteries. Because this protocol required performance of coronary angiography before initiation of thrombolytic therapy, many patients had relatively late initiation of reperfhsion at a time when the chances for myocardial salvage were diminished. In addition, TIMI Phase 1 was terminated early because of the highly significant difference in the primary end point: reperfusion rate. This action reduced the total number of patients available for ventricular function analysis. The present findings favoring treatment with rt-PA are not due to the relatively late initiation of therapy in the total study group. Reperfusion rates were also better for r&PA than for streptokinase in patients treated within 4 h of the onset of chest pain (Table 2) .
Previous reports. Similar modest changes in global and regional function were previously reported in the contrast ventriculographic analysis of TIMI Phase I (4) and in several other trials involving intracoronary (14-26) and intravenous (27-30) thrombolytic therapy. However, in TIM1 Phase I (4), contrast angiographic differences in left ventricular function were demonstrated only according to reperfusion status and by paired data analysis (that is, acute phase ventriculogram versus discharge ventriculogram). Moreover, the present study differs from the previous contrast angiographic study by the more complete data collection and the larger number of patients involved. Differences between treatment groups in average infarct region ejection fraction found in this study at the time of hospital discharge were not looked for in the contrast angiographic study (4). Differences between treatment groups for global ejection fraction were not statistically significant in the contrast angiographic study (4) or in the present study.
Conclusions. This is the first study involving a direct comparison of rt-PA and streptokinase thrombolytic therapy in which a strong suggestion exists that there is a relation between therapeutic efficacy assessed by infarct-related artery patency and functional improvement. Patients treated with rt-PA demonstrated better infarct region ejection frac-tion than did patients treated with streptokinase. However, this study was conducted with a sufficient number of patients to detect differences in reperfusion, and the differences in infarct region ejection fraction approached but did not exceed conventional significance (p = 0.05) levels. In patients who had successful thrombolysis and sustained reperfusion of the infarct-related artery, radionuclide angiocardiographic studies at hospital discharge demonstrated improvement of regional left ventricular function within the territory of the infarct artery, as well as trends toward improved global left ventricular function for infarcts related to the right coronary artery and infarcts related to the left anterior descending coronary artery. This study also illustrates the potential of quantitative radionuclide angiocardiography at hospital discharge for evaluating the benefits of early thrombolytic therapy on global and regional left ventricular function.
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